美国微卫星高度不稳定(MSI-H)或错配修复缺陷(dMMR)晚期子宫内膜癌患者的治疗模式与真实世界临床结局
本研究为回顾性病历审查,纳入124例既往系统治疗后进展且不适合根治性手术的MSI-H/dMMR晚期子宫内膜癌患者,比较化疗±贝伐珠单抗与免疫治疗的结局。化疗±贝伐珠单抗组中位真实世界无进展生存期(rwPFS)4.0个月、总生存期(OS)7.0个月,免疫治疗组分别为29.0个月和未达到。作者认为帕博利珠单抗单药带来可观临床获益并已成为标准治疗。
要点
- 124例MSI-H/dMMR晚期子宫内膜癌患者中,103例接受免疫治疗,21例接受化疗±贝伐珠单抗。
- 免疫治疗组中位rwPFS 29.0个月、OS未达到,化疗±贝伐珠单抗组分别为4.0个月和7.0个月。
- 92例接受帕博利珠单抗,其rwPFS 29.0个月、OS 30个月。
核心结论
- 真实世界证据提示帕博利珠单抗单药提供可观临床获益,已成为既往系统治疗后进展且不适合根治性手术的MSI-H/dMMR晚期子宫内膜癌患者在真实世界中的标准治疗。
研究设计与样本
- 子宫内膜癌健康结局(ECHO)研究为回顾性病历审查研究,纳入2016年7月1日至2018年12月31日期间既往系统治疗后进展且不适合根治性手术的MSI-H/dMMR晚期子宫内膜癌患者。
- 共124例符合条件的患者纳入,均启动二线化疗±贝伐珠单抗或免疫治疗。
- 采用Kaplan-Meier分析按药物类别分层估计真实世界无进展生存期(rwPFS)和总生存期(OS)。
主要发现
- 患者确诊晚期子宫内膜癌时平均年龄61.4岁,86.3%为IIIB-IV期。
- 21例接受化疗±贝伐珠单抗的患者中位rwPFS为4.0个月(95% CI:2.0-9.0),中位OS为7.0个月(95% CI:5.0-18.0)。
- 103例接受免疫治疗的患者中位rwPFS为29.0个月(95% CI:18.0-NE),中位OS未达到(95% CI:30.0-NA)。
- 92例接受帕博利珠单抗的患者中位rwPFS为29.0个月(95% CI:18.0-NE),中位OS为30个月(95% CI:30.0-NA)。
临床怎么用
- 作者认为,对于既往系统治疗后进展且不适合根治性手术的MSI-H/dMMR晚期子宫内膜癌患者,帕博利珠单抗单药在真实世界中提供可观临床获益并已成为标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Microsatellite instability-high (MSI-H) and deficient DNA mismatch repair (dMMR) status have emerged as actionable biomarkers for advanced endometrial cancer (aEC). The objective of this study was to assess clinical outcomes and treatment patterns among MSI-H/dMMR aEC patients who had disease progression following prior systemic therapy (FPST) in the US. METHODS: Endometrial Cancer Health Outcomes (ECHO) was a retrospective, medical chart review study of patients with MSI-H/dMMR aEC who had disease progression between 07/01/2016 and 12/31/2018 FPST and were not candidates for curative surgery. Data on patient demographics, clinical and treatment characteristics, and clinical outcomes were collected. Kaplan-Meier analyses were performed to estimate real-world progression-free survival (rwPFS) and overall survival (OS), stratified by drug class. RESULTS: A total of 124 eligible patients who initiated second-line chemotherapy ± bevacizumab or immunotherapy were included. Mean age was 61.4 years at aEC diagnosis and 86.3% of patients were stage IIIB-IV. Median rwPFS and OS were 4.0 months (95% CI: 2.0-9.0) and 7.0 months (95% CI: 5.0-18.0), respectively, among 21 patients who received chemotherapy ± bevacizumab, and 29.0 months (95% CI: 18.0-NE) and not reached (95% CI: 30.0-NA), respectively, among 103 patients who received immunotherapy. Most patients (n = 92) received pembrolizumab; among these patients, rwPFS and OS were 29.0 months (95% CI: 18.0-NE) and 30 months (95% CI: 30.0-NA), respectively. CONCLUSIONS: Real-world evidence suggests that pembrolizumab monotherapy provides considerable clinical benefits and has become the standard of care for MSI-H/dMMR aEC patients FPST who are not candidates for curative surgery in real-world settings.
引用
- Kelkar SS, Prabhu VS, Corman S, et al. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States. Gynecol Oncol. 2022. PMID: 36344294. doi:10.1016/j.ygyno.2022.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。